TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16113803

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 42
Study: 12395212

Group type: EXPERIMENTAL
Intervention: 60 min run (70 % of maximal speed)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rest for 60 min
Number of subjects: 18
Study: 10087117

Group type: EXPERIMENTAL
Intervention: True interval cancers
Number of subjects: 544

Group type: COMPARATOR
Intervention: Missed interval cancers
Number of subjects: 544

Group type: COMPARATOR
Intervention: Overlooked or misinterpreted tumours
Number of subjects: 544
Study: 8775611

Group type: EXPERIMENTAL
Intervention: Irrigation with dilute povidone-iodine solution after primary reclosure (Group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Simple reclosure with drains in the mediastinum (Group B)
Number of subjects: 55
Study: 3281708

Group type: EXPERIMENTAL
Intervention: 1% fusidic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3% gentamicin
Number of subjects: 40
Study: 30204921

Group type: EXPERIMENTAL
Intervention: Corn oil (4 tablespoons/day for 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coconut oil (4 tablespoons/day for 4 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coconut oil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Corn oil and Coconut oil
Number of subjects: 25
Study: 29202862

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Unusual Experiences (CBT-UED) plus routine care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 100
Study: 26288022

Group type: EXPERIMENTAL
Intervention: Subjective sleep quality (assessed with the Pittsburgh Sleep Quality Index)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Subjective sleep quality
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Psychological distress (measured using the Brief Symptom Inventory‐18)
Number of subjects: 158
Study: 23108011

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 300
Study: 21962046

Group type: EXPERIMENTAL
Intervention: Food Deprivation (FD) for up to 66 hours followed by 500 kcal intake over 24 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) for up to 50 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Food Deprivation (FD) for up to 66 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) for 50 hours
Number of subjects: 12
Study: 17621383

Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with citalopram
Number of subjects: 15

Group type: COMPARATOR
Intervention: Citalopram and placebo
Number of subjects: 15
Study: 19933408

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy in patients with Chagas disease
Number of subjects: 456
Study: 15588157

Group type: EXPERIMENTAL
Intervention: MTHFR 677C>T variant
Number of subjects: 591
Study: 12100056

Group type: EXPERIMENTAL
Intervention: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered intramuscularly.
Number of subjects: 60
Study: 9590465

Group type: EXPERIMENTAL
Intervention: Calcipotriene 30 g per day (15 g ointment twice a day for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 24
Study: 7871091

Group type: EXPERIMENTAL
Intervention: High dose of alpha-2 adrenoceptor antagonist
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2832091

Group type: EXPERIMENTAL
Intervention: DAMP-ES (schedule I: daily x5, doses of 10-90 mg/m2 per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAMP-ES (schedule II: 24-h continuous infusion, doses of 192 and 240 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended starting doses for phase II studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic studies of DAMP-ES
Number of subjects: 0
Study: 12375799

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11, Camptosar) and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of taxanes and irinotecan
Number of subjects: 0
Study: 30001358

Group type: EXPERIMENTAL
Intervention: Partograph utilization training
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Good knowledge about the partograph
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: On the job training in obstetric care
Number of subjects: 273
Study: 27425883

Group type: EXPERIMENTAL
Intervention: Postoperative models after bimaxillary orthognathic surgery with bone trimming at the inferior edge of the pyriform aperture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2-mm stenosis models
Number of subjects: 10
Study: 24738915

Group type: EXPERIMENTAL
Intervention: Cu-IUD
Number of subjects: 150

Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 150
Study: 22991128

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study: 20547079

Group type: EXPERIMENTAL
Intervention: 980 nm laser with bare-tip fibres
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1470 nm laser with radial fibres
Number of subjects: 60
Study: 18662179

Group type: EXPERIMENTAL
Intervention: PFO detected by transesophageal echocardiography
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: PFO detected by catheter probing
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: PFO presence
Number of subjects: 203

Group type: COMPARATOR
Intervention: Overall procedural success
Number of subjects: 203
Study: 15618041

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at baseline
Number of subjects: 5477

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation
Number of subjects: 5477
Study: 11853793

Group type: EXPERIMENTAL
Intervention: Chloramphenicol (25 mg/kg 6 hourly)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Benzylpenicillin (50 mg/kg 6 hourly) plus Gentamicin (7.5 mg/kg daily)
Number of subjects: 1116
Study: 10442869

Group type: EXPERIMENTAL
Intervention: Context reminder 24 hr before the 6‐month interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interviewed in the event context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (reminder but not the event)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context reminder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonverbal reminders
Number of subjects: 0
Study: 7876913

Group type: EXPERIMENTAL
Intervention: Stress management program including cognitive modification techniques and Stroebel's Quieting Response (QR) with biofeedback techniques
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress management program
Number of subjects: 40
Study: 2230269

Group type: EXPERIMENTAL
Intervention: Symptomatic HIV-infected individuals
Number of subjects: 65

Group type: COMPARATOR
Intervention: Asymptomatic individuals
Number of subjects: 65
Study: 328527

Group type: EXPERIMENTAL
Intervention: Counterimmunoelectrophoresis (CIEP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Complement fixation (CF) method
Number of subjects: 51
Study: 31325068

Group type: COMPARATOR
Intervention: Spermatozoa from the first ejaculate after several days of abstinence (Group 1, N = 121)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Spermatozoa from the second ejaculate after 1 hour of abstinence (Group 2, N = 144)
Number of subjects: 265
Study: 28805147

Group type: EXPERIMENTAL
Intervention: OTC lidocaine 3.6% with menthol 1.25%
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Rx lidocaine 5%
Number of subjects: 87
Study: 26458124

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (250 μg or 500 μg)
Number of subjects: 1482
Study: 23198836

Group type: EXPERIMENTAL
Intervention: Nigella
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Eucerin
Number of subjects: 60
Study: 21676368

Group type: EXPERIMENTAL
Intervention: Hydration plus systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure
Number of subjects: 128

Group type: COMPARATOR
Intervention: Hydration (control arm)
Number of subjects: 128
Study: 19407711

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/day)
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (flexible doses: 100-400 mg/day)
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2913
Study: 16940855

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg elemental zinc twice daily for 14 days)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (identical capsule for 14 days)
Number of subjects: 159
Study: 14760933

Group type: EXPERIMENTAL
Intervention: Non-ionic radiographic contrast media (RCM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ionic radiographic contrast media (RCM)
Number of subjects: 37
Study: 11081336

Group type: EXPERIMENTAL
Intervention: Juvenile chronic arthritis group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 0
Study: 8858666

Group type: EXPERIMENTAL
Intervention: BPIV-3 vaccine
Number of subjects: 30
Study: 1518260

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Postremission chemotherapy (CT-MC)
Number of subjects: 16
Study: 6434387

Group type: EXPERIMENTAL
Intervention: 10 mg nisoldipine after acute administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg nisoldipine at the end of three weeks of treatment (10 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil three times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (during one-week wash-out period)
Number of subjects: 12
Study: 31226936

Group type: EXPERIMENTAL
Intervention: Multimodal treatment: therapeutic workout program + medication review + diet adjustment + health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: medication review + diet adjustment + health education (regular workout recommendations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 29548651

Group type: EXPERIMENTAL
Intervention: rhTM (0.06mg/kg/day) for 6 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no rhTM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rhTM treatment
Number of subjects: 80
Study: 27574416

Group type: EXPERIMENTAL
Intervention: Roflumilast plus ICS/LABA FDC
Number of subjects: 2354

Group type: COMPARATOR
Intervention: Placebo plus ICS/LABA FDC
Number of subjects: 2354
Study: 25226757

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (protocol-defined pharmacist care)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Usual pharmacist care (control group)
Number of subjects: 734
Study: 22727500

Group type: EXPERIMENTAL
Intervention: PF-04457845 (4mg q.d.)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Naproxen (500mg b.i.d.)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 19780875

Group type: EXPERIMENTAL
Intervention: Adefovir plus Lamivudine (ADV/LAM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adefovir monotherapy (ADV)
Number of subjects: 60
Study: 17335695

Group type: EXPERIMENTAL
Intervention: Monolisa HCV Ag-Ab ULTRA
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Ortho HCV 3.0
Number of subjects: 1693
Study: 15591724

Group type: EXPERIMENTAL
Intervention: Modified mastectomy with adjuvant chemo- or radiation therapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Breast conserving surgery, lumpectomy and radiotherapy
Number of subjects: 206
Study: 11887170

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9516652

Group type: EXPERIMENTAL
Intervention: Smoking cessation (n = 100)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (continued smoking, n = 82)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Smoking cessation (n = 29 who fulfilled the study)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups (smoking cessation and control)
Number of subjects: 182
Study: 8041896

Group type: EXPERIMENTAL
Intervention: Preferred treatment for glottic laryngeal cancer
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Physicians' specialty
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Geographic location of practice
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Treatment recommendations for patients vs self
Number of subjects: 1649
Study: 3276390

Group type: EXPERIMENTAL
Intervention: 9 months of chemotherapy according to a modified Rosen schedule
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Elective bilateral lung irradiation of 20 Gy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 3 months of chemotherapy followed by lung irradiation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Radiotherapy arms
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher age or tibia localizations
Number of subjects: 205

Group type: COMPARATOR
Intervention: Chemotherapy arms
Number of subjects: 205

Group type: COMPARATOR
Intervention: Elective lung irradiation
Number of subjects: 205
Study: 4278358

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulphadimidine
Number of subjects: 40
Study: 31492492

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 9932

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 9932
Study: 26680684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methazolamide (250 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aminophylline (400 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methazolamide (250 mg) with Aminophylline (400 mg)
Number of subjects: 15
Study: 24291456

Group type: EXPERIMENTAL
Intervention: Thrice-weekly structured aerobic and resistance exercise intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health education condition
Number of subjects: 150
Study: 22951849

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 30
Study: 19833475

Group type: EXPERIMENTAL
Intervention: Patient-focused educational programs based on self-management (written and individualized action plan, self-monitoring, and regular medical review)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple provision of information about asthma
Number of subjects: 0
Study: 17524860

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day) started in the donor 6 days before donation and continued in recipient for 6 months after transplantation.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional immunosuppressive regimen (cyclosporine/mycophenolate mofetil and prednisolone).
Number of subjects: 10
Study: 15073670

Group type: EXPERIMENTAL
Intervention: ZYC101a
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 11772295

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapies aimed at eradicating chronic infections
Number of subjects: 0
Study: 9340898

Group type: EXPERIMENTAL
Intervention: PRO 160/120 (Sabal and Urtica extract)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 543
Study: 7880675

Group type: EXPERIMENTAL
Intervention: Midline approach with flexed lateral position (ML)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midline approach with sitting position (MS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paramedian approach with flexed lateral position (PL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paramedian approach with sitting position (PS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flexed sitting position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 100
Study: 2978875

Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP) 10 gm intravenously for three days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 15
Study: 2144803

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1099032

Group type: EXPERIMENTAL
Intervention: 10% urea cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cream with pH of 6
Number of subjects: 0
Study: 31488402

Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (HS) treatment (4 mL of 3% sodium chloride every 6 hours)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard supportive care (SC)
Number of subjects: 121
Study: 30885692

Group type: EXPERIMENTAL
Intervention: rAAV1‐PG9DP (4 × 10^12 to 1.2 × 10^14 vector genomes)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rAAV1‐PG9DP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 27815214

Group type: EXPERIMENTAL
Intervention: 40mg of propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40mg of placebo
Number of subjects: 0
Study: 25534727

Group type: EXPERIMENTAL
Intervention: LFF571 (200 mg four times daily for 10 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LFF571
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 72
Study: 23587029

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 7485

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 7485

Group type: EXPERIMENTAL
Intervention: Baseline HDL < 1.21 mmol/l
Number of subjects: 7485
Study: 21440948

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20186637

Group type: EXPERIMENTAL
Intervention: Forgiveness intervention (10 weekly interpersonal forgiveness therapy sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control therapy (10 weekly sessions)
Number of subjects: 32
Study: 17432640

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion (Group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular point sticking (Group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine acupuncture (Group C)
Number of subjects: 41
Study: 15956126

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 36
Study: 11550967

Group type: COMPARATOR
Intervention: Fas promoter -670 genotype (AA, GA, GG) in SLE patients
Number of subjects: 87

Group type: COMPARATOR
Intervention: Fas promoter -670 genotype (AA, GA, GG) in RA patients
Number of subjects: 87

Group type: COMPARATOR
Intervention: Fas promoter -670 genotype in second cohort of SLE patients (n = 85)
Number of subjects: 87
Study: 9596021

Group type: EXPERIMENTAL
Intervention: Cognitive test performance in African‐American Alzheimer's disease patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive test performance in European‐American Alzheimer's disease patients
Number of subjects: 0
Study: 7908357

Group type: EXPERIMENTAL
Intervention: c7E3 bolus/c7E3 infusion
Number of subjects: 2099

Group type: COMPARATOR
Intervention: c7E3 bolus/placebo infusion
Number of subjects: 2099
Study: 3047338

Group type: EXPERIMENTAL
Intervention: Vincristine (1 mg/m2) and prednisone (0.6 mg/kg/d for seven days at 8-week intervals)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone
Number of subjects: 589
Study: 29226610

Group type: EXPERIMENTAL
Intervention: Circulating concentrations of phenylalanine
Number of subjects: 12671

Group type: EXPERIMENTAL
Intervention: Circulating concentrations of acetate
Number of subjects: 12671

Group type: COMPARATOR
Intervention: Model with established risk factors and NT-proBNP
Number of subjects: 12671

Group type: EXPERIMENTAL
Intervention: Phenylalanine in FINRISK 1997
Number of subjects: 12671
Study: 26936139

Group type: EXPERIMENTAL
Intervention: 3 g high molecular weight (HMW) β‐glucan/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 g low molecular weight (LMW) β‐glucan/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 g low molecular weight (LMW) β‐glucan/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study: 24602973

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 81
Study: 22985900

Group type: EXPERIMENTAL
Intervention: Topical analgesic patches
Number of subjects: 30

Group type: COMPARATOR
Intervention: No drug patches (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional connectivity between left medial prefrontal cortex and bilateral insula
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-frequency oscillations in left dorsolateral prefrontal cortex
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of medial and lateral prefrontal functional connections
Number of subjects: 30
Study: 20004553

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 582

Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 582